Truist Financial Increases Amneal Pharmaceuticals (NASDAQ:AMRX) Price Target to $17.00

Amneal Pharmaceuticals (NASDAQ:AMRX) had its price objective increased by investment analysts at Truist Financial from $15.00 to $17.00 in a note issued to investors on Monday, MarketBeat Ratings reports. The brokerage currently has a “buy” rating on the stock. Truist Financial’s target price would suggest a potential upside of 27.72% from the company’s current price.

A number of other research analysts have also weighed in on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 21st. Barclays started coverage on Amneal Pharmaceuticals in a research report on Monday, December 8th. They issued an “overweight” rating and a $15.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, Amneal Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.20.

Amneal Pharmaceuticals Stock Down 3.3%

AMRX opened at $13.31 on Monday. The firm has a 50-day moving average price of $13.77 and a 200-day moving average price of $11.82. Amneal Pharmaceuticals has a twelve month low of $6.68 and a twelve month high of $15.42. The company has a market capitalization of $4.18 billion, a price-to-earnings ratio of 57.87 and a beta of 1.35.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Kemnay Advisory Services Inc. purchased a new stake in shares of Amneal Pharmaceuticals in the fourth quarter worth $26,000. Federated Hermes Inc. increased its stake in Amneal Pharmaceuticals by 1,680.6% in the 4th quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after acquiring an additional 2,168 shares during the last quarter. Comerica Bank raised its holdings in shares of Amneal Pharmaceuticals by 186.7% in the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after acquiring an additional 1,957 shares in the last quarter. Exchange Traded Concepts LLC bought a new stake in shares of Amneal Pharmaceuticals during the 3rd quarter valued at about $31,000. Finally, Spire Wealth Management boosted its position in shares of Amneal Pharmaceuticals by 66.6% during the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock valued at $32,000 after acquiring an additional 1,023 shares during the last quarter. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.